Brise Pharmaceuticals announces license agreement with AbbVie to advance migraine therapies
Brise said the agreement, entered in 2024, gives AbbVie global development and commercialization rights for two of Brise's preclinical migraine programs. The aggregated potential transaction value could reach up to US $757 million plus royalties on future sales.
Primary source
Company press release (PR Newswire), November 2, 2026
Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
Machine-summarized from the source above; not independently reported. How we use automation